New targets, new drugs for metastatic bone pain: A new philosophy

Expert Opinion on Emerging Drugs

Volumn 16, Issue 3, 2011, Pages 403-405

  Pantano, Francesco ^a   Zoccoli, Alice ^a   Iuliani, Michele ^a   Lanzetta, Gaetano ^b   Vincenzi, Bruno ^a   Tonini, Giuseppe ^a   Santini, Daniele ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b Istituto Neurotraumatologico Italiano   (Italy)

Author keywords

bone metastasis; denosumab; NGF; pain

Indexed keywords

CANNABINOID 2 RECEPTOR AGONIST; DENOSUMAB; GABAPENTIN; NERVE GROWTH FACTOR ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE DERIVATIVE; OSTEOCLAST DIFFERENTIATION FACTOR; STEROID; VANILLOID RECEPTOR 1 ANTAGONIST; ZOLEDRONIC ACID;

BONE METASTASIS; BONE PAIN; CANCER PAIN; CANCER RESEARCH; DRUG RESEARCH; DRUG TARGETING; HUMAN; IMMUNOTHERAPY; NEUROPATHIC PAIN; REVIEW; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIBODIES, MONOCLONAL; BONE NEOPLASMS; HUMANS; PAIN; RANK LIGAND;

EID: 80052006135     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.2011.588600     Document Type: Review

References (13)

1. Mercadante S. Malignant bone pain: Pathophysiology and treatment. Pain 1997;69:1-19
2. Christo PJ, Mazloomdoost D. Cancer pain and analgesia. Ann N Y Acad Sci 2008;1138:278-98
3. Ghilardi JR, Rohrich H, Lindsay TH, et al. Selective blockade of the capsaicin receptor TRPV1 attenuates bone cancer pain. J Neurosci 2005;25:3126-31
4. Lozano-Ondoua AN, Wright C, Vardanyan A, et al. A cannabinoid 2 receptor agonist attenuates bone cancer-induced pain and bone loss. Life Sci 2010;86:646-53
5. Sevcik MA, Ghilardi JR, Peters CM, et al. Anti-NGF therapy profoundly reduces bone cancer pain and the accompanying increase in markers of peripheral and central sensitization. Pain 2005;115:128-41
6. Halvorson KG, Kubota K, Sevcik MA, et al. A blocking antibody to nerve growth factor attenuates skeletal pain induced by prostate tumor cells growing in bone. Cancer Res 2005;65:9426-35
7. Pezet S, McMahon SB. Neurotrophins: Mediators and modulators of pain. Annu Rev Neurosci 2006;29:507-38
8. Lane NE, Schnitzer TJ, Birbara CA, et al. Tanezumab for the treatment of pain from osteoarthritis of the knee. N Engl J Med 2010;363(16):1521-31
9. A study of Tanezumab as add-on therapy to opioid medication in patients with pain due to cancer that has spread to bone. Available from: Http://clinicaltrials.gov/ct2/show/ NCT00545129
10. Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind study. J Clin Oncol 2010;28(35):5132-9
11. Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic Acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011;29(9):1125-32
12. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study. Lancet 2011;377(9768):813-22
13. Cleeland CS, Patrick DL, Fallowfield L, et al. Effects of denosumab vs zoledronic acid (ZA) on pain in patients (pts) with advanced cancer and bone metastases: An integrated analysis of 3 pivotal trials [abstract 1248P]. Presented at the 35th European Society for Medical Oncology (ESMO) Congress; 8 - 12 October 2010; Milan, Italy